Portfolio Finder

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.

650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers scientifically proven online psychotherapy courses to make fast and affordable care accessible to everyone. Courses are effective at treating symptoms by combining advanced technology with elements of traditional care.

Senostic is a diagnostics company developing a differential diagnostic test to detect multiple neurodegenerative diseases in a single test based on its proprietary SeedCylcer platform technology.

Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.

Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.

Simreka is a data-driven simulation platform that accelerates materials and manufacturing process innovation using AI by empowering brands and manufacturers reducing their R&D cycles and time-to-market. Simreka’s core engine has been developed on the scientific research of its co founder, Dr. Akshay Patel. The platform with its intuitive and secure enterprise application stack integrates data from various sources and uses artificial intelligence to map and process huge data-sets of chemicals and materials property, reactions, manufacturing processes and supply chains, using proprietary algorithms.

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists and one economist and develops disposable gloves for healthcare workers based on innovative materials. The double-layer gloves are optimized for infection control and tactile sensitivity, provide a dual contamination barrier, and visually indicate perforations from needle punctures. The two-in-one gloves are designed to replace double-cloving, which is practiced primarily during surgeries.

Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and to open up this market with new technologies.

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma.

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Tracekey offers a smart and lean track and trace solution as a Software-as-a-Service (SaaS) which enables our customers to make each product unique, distinctive and unequivocally verifiable in order to create and document an unbroken traceability over the entire product life cycle. As the first European supplier of a cloud based serialization solution tracekey focus on the pharmaceutical industry.

The circular bioeconomy startup traceless materials has developed a holistically sustainable alternative for plastics and bioplastics that is fully compostable in nature, contributing to solve the global plastic pollution.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

VACIS is the leading tissue engineering company for body-own blood vessels.
The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.

Volterion offers fully melted Stacks and flexible Elektrodes for use in Redox-Flow-Batteries and further implications.

WISE Srl is a Milan and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.

WMT developes small molecules for cancer indications by targeting the Warburg Metabolism. The Warburg Metabolism was first described 100 years ago by Otto Heinrich Warburg and the therapeutic approach is based on the fact that many cancer cells predominantly produce their energy through a high rate of glycolysis followed by lactic acid fermentation even in the presence of abundant oxygen. Using this mechanism for the treatment of cancer turns out to be very difficult, as interventions targeted at the sugar metabolism also cause harm to healthy cells. The approach WMT is using offers an improved therapeutic window as opposed to classical cancer medicines.

WPX Faserkeramik GmbH significantly improves energy efficiency and product quality in industrial heat treatment processes for metals by providing oxide fiber ceramic components made of patent registered Whipox® high performance ceramics used as refractories.

Zedira is a clinical stage biotech company specialized in the enzyme class of transglutaminases. Zedira performs drug discovery (e.g. celiac disease, diabetic nephropathy and thromboprophylaxis) and markets specialty reagents for R&D and diagnostics.